InvestorsHub Logo
Followers 5
Posts 557
Boards Moderated 0
Alias Born 06/23/2015

Re: None

Friday, 01/27/2017 10:12:03 AM

Friday, January 27, 2017 10:12:03 AM

Post# of 462435
Biogen and Eli Lilly ending partnerships left and right. The latest victim is Adocia, a French biotechnology company dedicated to protein delivery. Their BioChaperone® Lispro was licenced to Eli Lilly for the treatment of diabetes type 1. BioChaperone® Lispro is an insulin absorption accelerator. The word 'Chaperone' rang a bell and I googled 'Anavex' and 'diabetes':

'Patent No. 8,673,931 (the “Patent”). The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer’s disease (AD), type 2 diabetes and insulin resistance.'

I wonder what Anavex can bring to the table for diabetes patients.



http://www.adocia.fr/WP/products/biochaperone-ultra-fast-analog-insulin/

http://www.reuters.com/article/idUSFWN1FH05M?feedType=RSS&feedName=rbssHealthcareNews
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News